Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ibrutinib plus venetoclax in treatment-naive CLL/SLL
2016-002293-12Phase 2Active
- Sponsor
- Pharmacyclics
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Pharmacyclics. Primary endpoint: Primary endpoint (unspecified). Started Dec 2016; status: active.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2016-002293-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002293-12.